低剂量左甲状腺素降低2型糖尿病合并NAFLD患者肝内脂质含量
这项2b期单臂研究在新加坡六家医院纳入20例甲状腺功能正常的2型糖尿病合并超声诊断脂肪肝的男性患者,左甲状腺素滴定至促甲状腺激素0.34至1.70 mIU/L后维持16周。治疗后肝内脂质含量较基线下降12%(95%CI -3至0,P=0.046),体重指数、内脏及皮下脂肪体积小幅下降,糖代谢与血脂谱无显著变化。
要点
- 左甲状腺素滴定至TSH 0.34至1.70 mIU/L并维持16周后,肝内脂质含量较基线下降12%(P=0.046)。
- 体重指数(P=0.044)、内脏脂肪体积(P=0.047)和皮下脂肪体积(P=0.045)小幅下降。
- 糖代谢调控与血脂谱未见显著变化。
核心结论
- 本研究显示低剂量甲状腺激素治疗对男性NAFLD具有疗效和安全性。
- 甲状腺激素或甲状腺激素类似物可能对该病有益。
研究设计与样本
- 2b期单臂研究,在新加坡六家医院开展。
- 纳入甲状腺功能正常的2型糖尿病合并超声诊断脂肪肝患者,符合方案分析共20例男性。
- 左甲状腺素滴定至促甲状腺激素0.34至1.70 mIU/L,随后维持16周。
- 同时在诱导NAFLD的大鼠中测定肝内甲状腺激素浓度。
主要发现
- 符合方案分析20例男性基线特征:年龄47.8±7.8岁,体重指数30.9±4.4 kg/m2,基线肝内脂质含量13%±4%。
- 治疗后肝内脂质含量较基线下降12%(±SEM 26%),绝对变化为-2%(95%CI -3至0,P=0.046)。
- 体重指数(P=0.044)、内脏脂肪体积(P=0.047)和皮下脂肪体积(P=0.045)小幅下降。
- 糖代谢调控与血脂谱未见显著变化。
临床怎么用
- 原文结论认为低剂量甲状腺激素治疗对男性NAFLD具有疗效和安全性,甲状腺激素或甲状腺激素类似物可能对该病有益。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Nonalcoholic fatty liver disease (NAFLD) is highly prevalent in patients with type 2 diabetes mellitus (T2DM) and associated with significant morbidity and mortality. Thyroid hormone (TH) increases β-oxidation of fatty acids and decreases intrahepatic lipid content (IHLC) in rodents with NAFLD. OBJECTIVE: We investigated the possibility of low intrahepatic TH concentration in NAFLD and studied the effect of TH treatment in humans. DESIGN/SETTING: This was a phase 2b single-arm study in six hospitals in Singapore. Intrahepatic thyroid hormone concentrations were measured in rats with induced NAFLD. PATIENTS: Euthyroid patients with T2DM and steatosis measured by ultrasonography. INTERVENTION: Levothyroxine was titrated to reach a thyroid-stimulating hormone level of 0.34 to 1.70 mIU/L before a 16-week maintenance phase. MAIN OUTCOME MEASURES: The primary outcome measure was change in IHLC measured by proton magnetic resonance spectroscopy after treatment. RESULTS: Twenty male patients were included in the per-protocol analysis [mean ± SD: age, 47.8 ± 7.8 years; body mass index (BMI), 30.9 ± 4.4 kg/m2; baseline IHLC, 13% ± 4%]. After treatment, IHLC was decreased 12% (±SEM, 26%) relative to baseline (absolute change, -2%; 95% CI, -3 to 0; P = 0.046). Small decreases in BMI (P = 0.044), visceral adipose tissue volume (P = 0.047), and subcutaneous adipose tissue volume (P = 0.045) were observed. No significant changes in glucose regulation or lipid profile occurred. CONCLUSION: This study demonstrated the efficacy and safety of low-dose TH therapy for NAFLD in men. TH or TH analogs may be beneficial for this condition.
引用
- Bruinstroop E, Dalan R, Cao Y, et al. Low-Dose Levothyroxine Reduces Intrahepatic Lipid Content in Patients With Type 2 Diabetes Mellitus and NAFLD. J Clin Endocrinol Metab. 2018. PMID: 29718334. doi:10.1210/jc.2018-00475
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。